The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as cancer, asthma, type 2 diabetes and weight loss - Ozempic, Rybelsus and Wegovy. Austedo and Austedo XR, used to treat Huntington’s disease.

WASHINGTON — Medicare officials announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy, further complicating big decisions the Trump administration will have to make about how to cover the medications.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,

Researchers studied medical records of veterans who have diabetes. Prince Harry settles lawsuit with Murdoch papers after apology How To Invest In The S&P 500 (Step By Step) The Star Player Being Kept Out of Cooperstown by a Trash Can What the 14th Amendment says about birthright citizenship 10 Reliable Luxury Cars That Will Last You A Lifetime China's 'artificial sun' shatters nuclear fusion record by generating steady loop of plasma for 1,